Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis
| Autor: | Fabrizio Luppi, Marina Saetta, Elisabetta Balestro, Donato Lacedonia, Manuel G. Cosio, Elisabetta Cocconcelli, Stefania Cerri, Maria Pia Foschino Barbaro, Erica Bazzan, Dario Gregori, Paolo Spagnolo, Rosanna Milaneschi, Davide Biondini, Enrico Clini |
|---|---|
| Přispěvatelé: | Biondini, D, Balestro, E, Lacedonia, D, Cerri, S, Milaneschi, R, Luppi, F, Cocconcelli, E, Bazzan, E, Clini, E, Foschino Barbaro, M, Gregori, D, Cosio, M, Saetta, M, Spagnolo, P |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Vital capacity Pyridones Vital Capacity lcsh:Medicine Rate of decay Gastroenterology Article 03 medical and health sciences Idiopathic pulmonary fibrosis FEV1/FVC ratio 0302 clinical medicine forced vital capacity Internal medicine idiopathic pulmonary fibrosis pirfenidone forced vital capacity medicine Humans In patient 030212 general & internal medicine Longitudinal Studies Prospective Studies lcsh:Science Aged Multidisciplinary idiopathic pulmonary fibrosi business.industry Anti-Inflammatory Agents Non-Steroidal lcsh:R Pirfenidone Middle Aged respiratory system medicine.disease Idiopathic Pulmonary Fibrosis respiratory tract diseases Long term response Treatment Outcome 030228 respiratory system Disease Progression Female lcsh:Q pirfenidone business Progressive disease medicine.drug |
| Zdroj: | Scientific Reports, Vol 8, Iss 1, Pp 1-7 (2018) Scientific Reports |
| Popis: | Pirfenidone reduces functional decline in patients with Idiopathic Pulmonary Fibrosis (IPF). However, response to treatment is highly heterogeneous. We sought to evaluate whether response to pirfenidone is influenced by the pretreatment rate of forced vital capacity (FVC) decline. Fifty-six IPF patients were categorized as rapid (RP) or slow progressors (SP) based on whether their FVC decline in the year preceding pirfenidone treatment was > or ≤ 10% predicted. Following pirfenidone treatment patients were followed-up every 6 months and up to 24 months. In the entire population, pirfenidone reduced significantly FVC decline from 231 to 49 ml/year at 6 months (T6) (p = 0.003) and this effect was maintained at the 12-, 18- and 24-month time points (p value for trend n.s.). In RP, the reduction of FVC decline was evident at 6 months (36 vs 706 ml/year pretreatment; p = 0.002) and maintained, though to a lesser degree, at 12 (106 ml/year), 18 (176 ml/year) and 24 months (162 ml/year; p value for trend n.s). Among SP, the reduction in FVC decline was not significant at any of the time points analyzed. In conclusion, pirfenidone reduces FVC decline in IPF patients. However, its beneficial effect is more pronounced in patients with rapidly progressive disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|